MMB-2201

From WikiMD's Wellnesspedia

MMB-2201 is a synthetic cannabinoid that is also known as 5F-AMB-PICA and I-AMB. It is an indole-based synthetic cannabinoid, which is a type of designer drug. MMB-2201 is believed to act as a potent agonist for the CB1 receptor, which produces effects similar to those of THC, the primary psychoactive component of cannabis.

History[edit | edit source]

MMB-2201 was first identified in South Korea in 2014. It is part of the AMB-FUBINACA family of synthetic cannabinoids, which were first synthesized by the pharmaceutical company Pfizer in the early 2000s.

Effects[edit | edit source]

The effects of MMB-2201 are not well-studied, but it is believed to produce its effects by acting as an agonist for the CB1 receptor. This is similar to the action of THC, the primary psychoactive component of cannabis. However, the potency of MMB-2201 is believed to be significantly higher than that of THC.

Legal Status[edit | edit source]

The legal status of MMB-2201 varies by country. In the United States, it is a Schedule I controlled substance. In the United Kingdom, it is a Class B drug. In Canada, it is a Schedule II drug.

See Also[edit | edit source]

References[edit | edit source]


MMB-2201 Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD